Clinical Trials Browser

Phase 2 × INDUSTRY × futibatinib × Clear all

NCT05727176 2026-05-28

FOENIX-CCA4

Phase 2 Recruiting

Gastrointestinal

Cholangiocarcinoma

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT04601857 2025-12-31

Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Phase 2 Terminated

43 enrolled 15 charts

Advanced and Metastatic Urothelial Cancer

NCT04024436 2025-11-13

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Phase 2 Terminated

64 enrolled 21 charts

Breast Neoplasms

NCT04189445 2025-10-08

Futibatinib in Patients With Specific FGFR Aberrations

Phase 2 Terminated

115 enrolled 19 charts

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms